（文章来源：第一财经） 汇宇制药晚间公告，公司于2025年10月27日至2025年11月06日接受了来自美国食品药品监督管理局的现 行药品生产质量管理规范（cGMP）检查和药品批准前检查（PAI）。近日，公司收到了FDA签发的现 场检查报告（EIR），该报告表明FDA确认本次检查已结束，公司通过本次cGMP检查和药品批准前检 查（PAI）。 ...

Group 1 - The major shareholder, Huang Qianyi, held 27,219,439 shares, representing 6.426% of the total share capital before the passive reduction plan [1] - The passive reduction plan was executed due to a court order, resulting in the forced sale of 1,300,000 shares, which are all unrestricted circulating shares [1] - The completion of the passive reduction was confirmed on February 10, 2026, with a total of 1,300,000 shares sold, accounting for 0.307% of the current total shares [2] Group 2 - The reduction was in compliance with relevant laws and regulations, and the actual reduction matched the previously disclosed plan [3] - There were no violations of the reduction plan or other commitments during the process [3]

Group 1 - Baichuan Co., Ltd. announced a recent price increase for some of its main products due to market supply and demand factors, but the sustainability of this price fluctuation remains uncertain, making it difficult to predict the impact on the company's performance [1] - Jincheng Co., Ltd. plans to increase its acquisition of CMH Company by an additional 42.50% stake, which will give it a total ownership of 97.5% and ultimate control over CMH [2] - Xinhang New Materials intends to raise no more than 1 billion yuan through a private placement of A-shares, with the funds allocated for projects including high-performance resin production and a composite materials innovation center [3] Group 2 - SMIC reported a sales revenue of $2.489 billion for Q4 2025, a 4.5% increase quarter-on-quarter, with an annual revenue of $9.327 billion, reflecting a 16.2% year-on-year growth [4] - China Railway Construction recently won 10 major projects, each valued over 1.5 billion yuan, totaling 45.142 billion yuan, which represents 4.23% of the company's audited revenue for 2024 [5] - Shenzhen Airport recorded a passenger throughput of 5.8795 million in January 2026, a year-on-year increase of 2.84% [6] Group 3 - China State Construction reported a new contract total of 399.5 billion yuan in January 2026, marking a 1.8% year-on-year increase [7] - Jindi Group's sales amount in January 2026 decreased by 45.78% year-on-year, with a signed area of 78,000 square meters [8] - Changyuan Power achieved a power generation of 3.971 billion kWh in January 2026, a year-on-year increase of 37.81% [9] Group 4 - Senyuan Electric is expected to win a project from the Southern Power Grid valued at 272 million yuan [10] - Chengyi Pharmaceutical's products are set to be selected for the national centralized procurement of expiring varieties [12] - Xinwufeng reported a 10.71% year-on-year decrease in pig sales volume in January 2026 [13] Group 5 - Shengnong Development's sales revenue in January 2026 increased by 40.48% year-on-year, with chicken sales volume rising by 42.79% [14] - Minglida announced the termination of its investment in a key component manufacturing project due to global economic uncertainties [15] - CITIC Securities reported that its subsidiary, Huaxia Fund, achieved a net profit of 2.396 billion yuan in 2025 [16] Group 6 - Pianzaihuang completed the first subject enrollment for its Phase II clinical trial of PZH2107 [17] - Xinzhou Bang reported a 16.56% year-on-year increase in net profit for 2025 [18] - Ankai Bus produced 761 vehicles in January 2026, a year-on-year increase of 35.65% [19] Group 7 - Weilan Bio plans to acquire a 50% stake in Aidimeng Weilan for 47 million yuan [20] - Ningbo Gaofa intends to establish a wholly-owned subsidiary with an investment of no more than 100 million yuan [21] - Shanghai Airport signed a leasing contract worth approximately 585 million yuan with the Shanghai Airport Group [22] Group 8 - Fosun Pharma's subsidiary received acceptance for a drug registration application [23] - Jindai Home's subsidiary invested in acquiring shares in a North American market company [24] - Huatong Co. reported a 1.45% year-on-year decrease in pig sales revenue in January 2026 [25] Group 9 - Yunnan Energy Investment's Nanchong Wind Power Project has been approved with a total installed capacity of 62,500 kW [28] - Youyan Silicon reported a 10.14% year-on-year decrease in net profit for 2025 [29] - Jinpu Titanium announced a temporary shutdown of its Nanjing Titanium White production due to reduced demand [30] Group 10 - Yipin Hong completed the sale of its stake in Arthrosi for a total of $9.5 billion in upfront payments [31] - Liande Co. stated that its gas turbine business currently has limited supply, with minimal impact on overall performance [32] - Tiens Wind Power signed new contracts worth 870 million yuan in the offshore engineering sector [33] Group 11 - Daqin Railway reported a freight volume of 31.28 million tons in January 2026, a year-on-year increase of 5% [34] - ST Mingcheng successfully dismissed all claims from Beijing Fusheng in a recent court ruling [35] - Zhiyang Innovation is planning to acquire control of Lingming Photon and will continue its stock suspension for up to five trading days [36][37] Group 12 - Fulai New Materials accelerated the commercialization of flexible sensors, preparing for mass production of its third-generation electronic skin products [38] - Minhe Co. reported a 36.89% year-on-year decrease in sales of broiler chicks in January 2026 [39] - Ruiang Gene received government subsidies totaling 2 million yuan [40] Group 13 - Huiyu Pharmaceutical's shareholder was forced to reduce holdings by 0.307% due to a court order [41] - Fuyuan Pharmaceutical's subsidiary obtained a drug registration certificate for a new oral solution [42] - Xuantai Pharmaceutical's product is set to be selected for national procurement [43] Group 14 - Chunqiu Electronics completed the cancellation of 9.1369 million repurchased shares [44] - Jinguang Electric won a bid worth approximately 28.8691 million yuan [45] - Hongda Co. plans to invest approximately 71.43 million yuan in a 110kV power transmission project [46] Group 15 - Nanchao Foods reported a 1.99% year-on-year decrease in revenue for January 2026 [47] - Shisheng Intelligent plans to repurchase shares worth between 17.5 million and 35 million yuan [48]

Core Viewpoint - The company Huayu Pharmaceutical announced that shareholder Huang Ganyi was forced by the Sichuan Anyue County People's Court to sell 1.3 million shares of unrestricted circulating stock, which represents a passive reduction in holdings [1] Group 1: Shareholder Reduction - The reduction period for the shares is from February 9, 2026, to February 10, 2026, and the shares will be sold through centralized bidding [1] - The price range for the reduction is between 19.41 to 19.77 yuan per share, resulting in a total reduction amount of 25.4803 million yuan [1] - The reduced shares account for 0.307% of the company's total share capital [1] Group 2: Shareholding Status Post-Reduction - After the reduction, Huang Ganyi holds 25.9194 million shares, which is 6.119% of the total shares [1] - Previously, Huang Ganyi held 27.2194 million shares, representing 6.426% of the total shares [1] - The passive reduction has been completed [1]

证券代码：688553 证券简称：汇宇制药 公告编号：2026-008 四川汇宇制药股份有限公司 持股 5%以上股东被动减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有股份的基本情况 本次被动减持计划实施前，四川汇宇制药股份有限公司(以下简称"公司") 股东黄乾益持有公司股份数量为 27,219,439 股，占公司总股本的 6.426%， 上述股份来源于公司首次公开发行前取得的股份，且上述股份已被司法冻 结，全部为无限售流通股。 2026 年 2 月 10 日，公司收到股东黄乾益先生出具的《关于被动减持 股份实施完成的告知函》，股东黄乾益先生通过集中竞价交易方式合计被动 减持所持公司股份 1,300,000 股，占公司目前总股份的 0.307%，本次被动 减持已实施完成。现将有关股份被动减持实施结果公告如下： 1 上述减持主体无一致行动人。 二、减持计划的实施结果 （一）大股东因以下事项披露减持计划实施结果： 其他情形：股份被司法强制执行实施完成 | 股东名称 | 黄 ...

Core Viewpoint - The announcement from Huiyu Pharmaceutical indicates that shareholder Huang Qianyi has reduced his stake in the company due to judicial enforcement actions, impacting his overall shareholding percentage and total shares held [1] Group 1: Shareholding Details - Huang Qianyi held 27,219,439 shares before the reduction, representing 6.426% of the total share capital [1] - Following the reduction, Huang Qianyi now holds 25,919,439 shares, which is 6.119% of the total share capital [1] Group 2: Reduction Specifics - The reduction occurred between February 9 and 10, 2026, through centralized bidding transactions [1] - A total of 1,300,000 shares were sold, accounting for 0.307% of the current total shares [1] - The share reduction was executed at a price range of 19.41 to 19.77 yuan per share, resulting in a total amount of 25.4803 million yuan [1] Group 3: Compliance and Plan - The share reduction was completed in accordance with relevant regulations and aligned with the previously announced reduction plan [1]

Core Viewpoint - Sichuan is focusing on high-quality development of the biopharmaceutical industry, aiming to establish itself as an innovation hub in Western China, with an emphasis on accelerating the transformation of scientific research achievements into accessible quality medicines for the public [1][3]. Group 1: Innovation and Regulatory Efficiency - The chairman of Sichuan Huiyu Pharmaceutical Co., Ding Zhao, highlighted the importance of efficient communication between enterprises and regulatory departments to expedite the approval process for new drugs [3]. - Ding proposed the establishment of a regional drug review center within the Chengdu-Chongqing economic circle to enhance the efficiency of drug approvals, which could significantly benefit local pharmaceutical companies [3]. - The establishment of the "Southwest Drug Review Center" is anticipated to be a major advantage for pharmaceutical enterprises in Sichuan and Chongqing by 2025 [3]. Group 2: Drug Pricing and Collection Policies - Ding emphasized the need to optimize drug collection policies to lower inflated drug prices, ensuring affordability for patients while maintaining the sustainability of medical insurance funds [3]. - The recent improvements in collection policies are seen as a positive development, balancing patient accessibility, insurance sustainability, and the innovation incentives for companies [3][4]. Group 3: Collaborative Innovation and Data Integration - Ding called for the government to lead efforts in integrating clinical data from research institutions and medical facilities to promote the deep integration of "artificial intelligence + medicine" [4]. - There is a push for better collaboration among research institutions, innovative pharmaceutical companies, and regulatory bodies to accelerate the transformation of innovative results into effective treatments [4]. - The expectation is that continuous policy innovation and systematic support will help Sichuan cultivate more globally competitive biopharmaceutical innovators [4].

Core Viewpoint - Huiyu Pharmaceutical is expected to report a significant decline in revenue and net profit for the year 2025, marking its first loss since its listing in 2021 [1] Group 1: Financial Performance - The company forecasts a revenue range of 960 million to 1.09 billion yuan for 2025, representing a year-on-year decline of 12.28% to 0.40% [1] - The projected net profit attributable to the parent company is expected to be a loss between 29 million and 24 million yuan, indicating a year-on-year decline of 108.91% to 107.38% [1] - Historical net profits from 2021 to 2024 were 446 million, 249 million, 140 million, and 325 million yuan respectively [1] Group 2: Reasons for Loss - The anticipated loss is primarily attributed to fair value changes resulting from the stock price fluctuations of Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., which was listed on the Hong Kong Stock Exchange on August 20, 2024 [1] Group 3: Shareholder Developments - Prior to the earnings warning, the company disclosed that its second-largest shareholder, Huang Qianyi, would face judicial forced reduction of shares [1] - Huang Qianyi is the son of Huang Bingquan, one of the core founders of Huiyu Pharmaceutical [1] Group 4: Market Reaction - On January 29, the company's stock fell by 2.74%, with a total market capitalization of 8.112 billion yuan, marking a cumulative decline of over 8% over five consecutive days [2]

Core Viewpoint - The company, Huyou Pharmaceutical, anticipates a significant decline in net profit for the fiscal year 2025, projecting a loss between 29 million to 24 million yuan, which represents a year-over-year decrease of 108.91% to 107.38% [2] Financial Performance - The expected net profit attributable to the parent company for 2025 is projected to be between -29 million yuan and -24 million yuan [2] - The anticipated operating revenue for 2025 is estimated to be between 960 million yuan and 1.09 billion yuan [2]

Core Viewpoint - Huiyu Pharmaceutical (688553) is expected to report a net profit attributable to shareholders of between -24 million to -29 million yuan for 2025, representing a year-on-year decline of 107.38% to 108.91% compared to the previous year [1] Group 1: Financial Performance - The projected net profit for 2025 indicates a significant loss, with estimates ranging from -24 million to -29 million yuan [1] - This represents a drastic decline of over 100% compared to the previous year's legally disclosed data [1] Group 2: Investment Impact - The company’s investment in Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd. is set to be listed on the Hong Kong Stock Exchange on August 20, 2024, under the stock code 02410.HK [1] - Fluctuations in the stock price of the invested enterprise have led to a fair value change loss of 173 million yuan during the reporting period [1]